Active ingredients: bezlotoxumab
What it is used for
ZINPLAVA (bezlotoxumab) is indicated for the prevention of recurrence of Clostridium difficile infection (CDI) in adult patients 18 years or older at high risk for recurrence of CDI who are receiving antibiotic therapy for CDI (see CLINICAL TRIALS). ZINPLAVA is not indicated for the treatment of CDI. ZINPLAVA is not an antibacterial drug. ZINPLAVA should only be used in conjunction with antibacterial drug treatment of CDI. The safety and efficacy of repeat administration of ZINPLAVA in patients with CDI have not been studied.
How to take it
The way to take this medicine is: Intravenous. This medicine or fluids is given through a needle or tube (catheter) inserted into a vein.
- Store at 2 to 8 degrees Celsius
- Do not Freeze
- Protect from Light
- Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Clear to moderately opalescent, colourless to pale yellow liquid, essentially free from visible particles.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient bezlotoxumab
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems